This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI) Identifier:
First received: March 3, 2005
Last updated: June 21, 2013
Last verified: December 2006

RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Trastuzumab may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well trastuzumab works in treating patients with locally advanced or metastatic synovial sarcoma.

Condition Intervention Phase
Sarcoma Biological: trastuzumab Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Response rate (confirmed complete response and partial response)

Secondary Outcome Measures:
  • Progression-free survival at 1 and 2 years
  • Overall survival at 1 and 2 years
  • Toxicity

Estimated Enrollment: 40
Study Start Date: July 2005
Study Completion Date: August 2007
Detailed Description:



  • Determine the response rate (confirmed complete response and partial response) in patients with HER2/neu-overexpressing locally advanced or metastatic synovial sarcoma treated with trastuzumab (Herceptin^®).


  • Determine the frequency and severity of toxic effects of this drug in these patients.
  • Determine overall survival and progression-free survival of patients treated with this drug.
  • Correlate, preliminarily, SYT-SSX translocation, HER2/neu expression, and monophasic and biphasic phenotype with clinical outcomes in patients treated with this drug.

OUTLINE: This is a pilot, multicenter study.

Patients receive trastuzumab (Herceptin^®) IV over 90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed every 6 weeks until disease progression and then every 6 months for up to 2 years from study entry.

PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 10-40 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed synovial sarcoma meeting 1 of the following stage criteria:

    • Locally advanced disease, defined as 1 of the following:

      • Incurable by conventional multidisciplinary therapy, including surgery
      • Surgically resectable only with significant morbidity
    • Metastatic disease
  • Tumor HER2/neu positive (2+ or 3+) by immunohistochemistry
  • Tumor tissue must be available AND patient must be willing to allow specimen submission
  • Measurable disease
  • No known CNS metastases



  • 18 and over

Performance status

  • Zubrod 0-2

Life expectancy

  • Not specified


  • Absolute neutrophil count > 1,000/mm^3
  • Hemoglobin > 8 g/dL
  • Platelet count > 100,000/mm^3


  • Bilirubin < 1.5 times upper limit of normal (ULN)
  • SGOT and/or SGPT < 1.5 times ULN (5 times ULN if liver metastases are present)


  • Creatinine < 1.5 times ULN OR
  • Creatinine clearance > 60 mL/min


  • LVEF > 45% by MUGA


  • No active peptic ulcer disease
  • No active gastrointestinal bleeding
  • No active inflammatory bowel disease


  • Not pregnant or nursing
  • Fertile patients must use effective contraception
  • No known HIV positivity
  • No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission


Biologic therapy

  • No concurrent filgrastim (G-CSF)


  • At least 3 weeks since prior chemotherapy

Endocrine therapy

  • Not specified


  • At least 60 days since prior radiotherapy to the target lesion*
  • No concurrent radiotherapy NOTE: *Lesion must have demonstrated disease progression after completion of therapy


  • At least 21 days since prior major surgery and recovered


  • At least 60 days since prior embolization or radiofrequency ablation to the target lesion* NOTE: *Lesion must have demonstrated disease progression after completion of therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00104949

Sponsors and Collaborators
Southwest Oncology Group
National Cancer Institute (NCI)
OverallOfficial: Ernest C. Borden, MD The Cleveland Clinic
OverallOfficial: Rashmi Chugh, MD University of Michigan Cancer Center
OverallOfficial: George D. Demetri, MD Dana-Farber Cancer Institute
OverallOfficial: Margaret von Mehren, MD Fox Chase Cancer Center
OverallOfficial: Vivien H.C. Bramwell, MB, BS, PhD, FRCP Tom Baker Cancer Centre - Calgary
OverallOfficial: Karen H. Albritton, MD Dana-Farber Cancer Institute
  More Information Identifier: NCT00104949     History of Changes
Other Study ID Numbers: CDR0000413703
Study First Received: March 3, 2005
Last Updated: June 21, 2013

Keywords provided by National Cancer Institute (NCI):
adult synovial sarcoma
recurrent adult soft tissue sarcoma
stage III adult soft tissue sarcoma
stage IV adult soft tissue sarcoma

Additional relevant MeSH terms:
Sarcoma, Synovial
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Connective Tissue
Antineoplastic Agents processed this record on August 18, 2017